Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Meiji Seika to Strengthen Its Overseas Business Structures: Vice President Ogawa
January 29, 2001
- PAJ President Uehara Stresses Importance of Self-medication
January 29, 2001
- National Burden Rate Can Be Reduced 10% Through Reform: Koseisho Study Team
January 29, 2001
- Council to Study Ways to Supply Drug Information to Public
January 29, 2001
- Jovi to Increase Its Member Stores to 3,000
January 29, 2001
- REGULATORY NEWS IN BRIEF
January 29, 2001
- JIRA Aims at Introducing Medical Devices Law
January 29, 2001
- Clinical Trial Support System Established in 5 Nat'l Univ.
January 29, 2001
- Olympus Aims at \100 Bil. Sales with Genomic Healthcare
January 29, 2001
- In vitro Fertilization Using Sperm, Ova from Third Parties to Be Approved
January 29, 2001
- Economy, Trade, Industry Ministry to Help Handicapped Persons Obtain Access to Internet
January 29, 2001
- Daiichi Forms Alliance with MedGene
January 22, 2001
- R&D Investment by 9 Major Companies Increases 3.5% in First 6 Months
January 22, 2001
- SCRIP Tokyo Office Moves
January 22, 2001
- Daiichi Pure Chemicals Starts Contract SNP Analysis Services
January 22, 2001
- Merger with Mitsui Pharm Strengthens Schering Group's Product Line
January 22, 2001
- 15 Researchers Win AstraZeneca Asthma Research Award
January 22, 2001
- Cancer to Be Next 'Franchise' Area Following CNS, GI Fields: Mr Shinoda of Eisai
January 22, 2001
- New Kosei-Rodosho Inaugurated on Jan. 6
January 22, 2001
- Kyushu Univ. Opens Master's Course to Train Specialized Medical Professionals
January 22, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…